528 material Form 8-K filings that 462 companies we cover made with the SEC in January 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Merit Medical said preliminary unaudited revenue for the year ended December 31, 2024 is about $1.355 billion to $1.357 billion, up about 7.7% to 7.9% from the prior year. The figures are unaudited and may change after the audit, and the company plans to report full fourth-quarter and 2024 results and 2025 guidance on February 25, 2025.
Preliminary 2024 revenue of about $1.355 billion to $1.357 billion, up about 7.7% to 7.9% year over year
Preliminary constant currency revenue increased about 8.4% to 8.6%; the foreign exchange impact is $7.9 million
Audited results are not yet available, and the auditor has not reviewed the preliminary figures
Full 2024 results and fiscal 2025 guidance are scheduled for February 25, 2025 after market close
Exelixis reported preliminary, unaudited fiscal 2024 results and gave 2025 guidance, with total revenues of about $2.165 billion and net product revenues of about $1.805 billion for 2024. The audit is ongoing and the figures could change, with audited results due February 11, 2025. The 2025 net product revenue guidance of $1.95 billion to $2.05 billion sits above the 2024 preliminary figure, which points to expected growth for the cabozantinib franchise.
Preliminary fiscal 2024 total revenues of about $2.165 billion and net product revenues of about $1.805 billion
2025 guidance: total revenues of $2.15 billion to $2.25 billion; net product revenues of $1.95 billion to $2.05 billion
2025 research and development expenses guided at $925 million to $975 million; SG&A at $475 million to $525 million
Audited fiscal 2024 results scheduled for release February 11, 2025; the figures could change before then
Alignment Healthcare said it had about 209,900 health plan members as of January 1, 2025, up about 35% year over year, and expects 225,000 to 231,000 members by December 31, 2025. It reaffirmed its 2024 guidance and its confidence in about $40 million of adjusted EBITDA in 2025, with 2025 guidance to come on its fourth-quarter earnings call. The filing also says Dawn Maroney was promoted to President, effective immediately, to oversee day-to-day operations, while the filing provides no fourth-quarter or full-year 2024 results.
Health plan membership of about 209,900 as of January 1, 2025, up about 35% from January 1, 2024
Expects 225,000 to 231,000 members as of December 31, 2025, about 22% to 25% growth versus the midpoint of year-end 2024 membership guidance
Reaffirmed 2024 guidance: revenue of $2,665 million to $2,680 million and adjusted EBITDA of ($10) million to $5 million
Dawn Maroney promoted to President effective January 13, 2025; she reports to founder and CEO John Kao
Xencor said its preliminary, unaudited cash, cash equivalents and marketable debt securities were about $707 million at December 31, 2024, compared with $697.0 million a year earlier. The company expects this cash to fund research and development and operations into 2028, and the figures may change after year-end closing and audit procedures.
Preliminary, unaudited cash, cash equivalents and marketable debt securities of about $707 million at December 31, 2024, versus $697.0 million at December 31, 2023
Based on current operating plans, Xencor expects cash to fund research and development programs and operations into 2028
January 13, 2025 investor presentation also updated XmAb808 to resumed dose escalation and reported completed enrollment in three vudalimab studies
Progyny said on January 13, 2025 that fourth-quarter 2024 revenue, net income and Adjusted EBITDA are now expected to be slightly above the ranges it gave in November. The company said member activity paced better than its guidance assumed, which had expected activity to be flat to down. The filing gives no specific dollar figures for the updated expectations.
Updated expectations cover the quarter and year ending December 31, 2024, and were issued January 13, 2025 in Exhibit 99.1.
Revenue, net income and Adjusted EBITDA for Q4 2024 are now expected to be slightly above the November guidance ranges.
CEO Pete Anevski will present at the JP Morgan Healthcare Conference on January 14, 2025 at 7:30 a.m. Pacific Time.
Alnylam said preliminary full-year 2024 global net product revenues were $1,646 million, up 33% from 2023, and fourth-quarter revenues were approximately $451 million. The company also guided to 2025 combined net product revenue of $2,050 million to $2,250 million and expects non-GAAP operating income profitability in 2025, which matters to shareholders because it sets the company's first public outlook for the year. The figures are unaudited and subject to adjustment before full results in February 2025.
Preliminary Q4 2024 global net product revenues were approximately $451 million; full-year 2024 was $1,646 million, up 33%.
2025 combined net product revenue guidance is $2,050 million to $2,250 million, or 31% growth at the midpoint.
Total TTR guidance is $1,600 million to $1,725 million; Total Rare guidance is $450 million to $525 million.
Full results are due in February 2025; the vutrisiran heart-disease PDUFA target action date is March 23, 2025.
Revvity said preliminary fourth-quarter 2024 revenue growth of about 5% reported and 6% organic, which it expects to produce revenue of about $730 million. It also now expects full-year 2024 adjusted earnings per share to meet or exceed guidance given on November 4, 2024. Full results are due before market open on January 31, 2025.
Q4 2024 reported revenue growth expected at about 5%, organic growth about 6%
Q4 2024 revenue expected at approximately $730 million
Full-year 2024 adjusted EPS expected to meet or exceed the November 4, 2024 guidance
Full Q4 and full-year 2024 results and earnings call on January 31, 2025; CEO Prahlad Singh presents at J.P. Morgan Healthcare Conference on January 13, 2025
Shake Shack reported preliminary, unaudited fourth-quarter and fiscal 2024 results, with fourth-quarter total revenue of $328.7 million, up 14.8%, and Adjusted EBITDA of $46.5 million, up 48% year over year. The company also gave initial 2025 guidance of $1.45 billion to $1.48 billion in total revenue and $200 million to $210 million in Adjusted EBITDA, and said it now sees its Company-operated footprint reaching at least 1,500 Shacks over time, up from a prior target of 450.
Q4 2024 total revenue $328.7 million; FY2024 total revenue $1.3 billion; same-Shack sales up 4.3% in Q4
Q4 2024 Adjusted EBITDA $46.5 million, up 48%; restaurant-level profit margin about 22.7% of Shack sales
2025 guidance: total revenue $1.45 billion to $1.48 billion; Adjusted EBITDA $200 million to $210 million; net income $45 million to $60 million
Long-term Company-operated Shack target raised to at least 1,500 from 450; results are preliminary and unaudited pending the Form 10-K
ADMA Biologics preliminarily estimated unaudited total 2024 revenue of $417-425 million, above its previous guidance of $415 million, and said year-end 2024 cash grew to more than $100 million. The company also expects 2025 total revenue above $485 million and net income above $170 million, which gives shareholders updated figures for the year ahead.
Preliminary unaudited FY 2024 total revenue of $417-425 million, versus previous guidance of $415 million
Year-end 2024 total cash above $100 million, up about $45 million quarter over quarter, after $30 million of debt discharged in Q4 2024
FY 2025 total revenue expected to exceed $485 million and net income to exceed $170 million; FY 2026 revenue expected above $600 million
PAS submitted to the FDA for yield enhancement production process; approval anticipated mid-2025
Option Care Health reported preliminary, unaudited fourth-quarter and full-year 2024 results, with full-year net revenue of about $4.99 billion to $5.00 billion, up 16.0% to 16.2%, and adjusted diluted EPS of $1.55 to $1.59. For 2025 it expects net revenue of $5.2 billion to $5.4 billion and adjusted EPS of $1.59 to $1.69, including a $60 million to $70 million gross profit reduction tied to Stelara pricing adjustments. The Board also approved a new $500 million share repurchase program with no specified expiration date.
Q4 2024 net revenue of about $1.34 billion to $1.35 billion, up 19.2% to 20.1% year over year
Full-year 2024 adjusted diluted EPS of $1.55 to $1.59; GAAP diluted EPS of $1.21 to $1.23
2025 guidance: net revenue of $5.2 billion to $5.4 billion and adjusted EBITDA of $445 million to $465 million
New $500 million share repurchase program approved January 10, 2025; full results due February 26, 2025
Pediatrix Medical Group said Executive Chair Mark S. Ordan will return as chief executive, effective immediately, succeeding James D. Swift, M.D. The company also said it currently believes it will reach the high end of its $205 million to $215 million 2024 adjusted EBITDA outlook and that the result may exceed that range, which would be an upward move from the prior guidance.
Mark S. Ordan appointed CEO effective immediately, succeeding James D. Swift, M.D., who will assist during the transition
Prior 2024 adjusted EBITDA outlook was $205 million to $215 million; company now expects the high end or possibly more
Fourth quarter and full year 2024 results to be announced February 20, 2025
Inspire Medical Systems reported preliminary, unaudited fourth-quarter 2024 revenue of $239.5 million to $239.7 million, about 25% higher than a year earlier, and full-year 2024 revenue of $802.6 million to $802.8 million, up about 28%. The company also gave initial 2025 revenue guidance of $940 million to $955 million, a 17% to 19% increase, and announced leadership changes, including a new Chief Manufacturing and Quality Officer. The figures are estimates that may change before the full 2024 results are reported in the Form 10-K.
Preliminary Q4 2024 revenue of $239.5 million to $239.7 million, up about 25% year over year
Preliminary full-year 2024 revenue of $802.6 million to $802.8 million, up about 28%
Initial 2025 revenue guidance of $940 million to $955 million, a 17% to 19% increase
Jason Kelly named Chief Manufacturing and Quality Officer effective January 20, 2025; Chief Medical Officer Charisse Sparks left the company at the beginning of 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.